Abstract O17 Table 1 SLESIS-R index calculator

Predictor	Score
Age (years) ≥60	4
Previous SLE-related hospitalization	4
Previous serious infection	4
GC doses	
>5 mg and <10 mg	2
≥10 mg and <30 mg	2
≥30 mg	5

SLESIS-R: Systemic Lupus Erythematosus Infection Score-Revised; SLE: systemic lupus erythematosus; GC: glucocorticoids

Society of Rheumatology. A multivariable logistic model was constructed taking into account the variables already forming the SLESIS score, plus all other potential predictors identified in a literature review. Performance was analyzed using the C statistic and the area under the ROC (AUROC). Internal validation was carried out using a 100-sample bootstrapping procedure. OR were transformed into score items, and the AUROC was used to determine performance.

Results A total of 1459 patients who had completed 1 year of follow-up were included (mean age, 49 ± 13 years; 90% females). Twenty-five (1.7%) had experienced ≥1 severe infection. According to the adjusted multivariate model, severe infection could be predicted from 4 variables: age (years) ≥60, previous SLE-related hospitalization, previous severe infection, and glucocorticoid dose. A score was built from the best model (table 1). AUROC:0.861 (0.777–0.946). The cut-off chosen was ≥6, which exhibited an accuracy of 85.9% and a positive LR of 5.48.

Conclusions SLESIS-R is an accurate and feasible instrument for predicting infections in SLE patients. SLESIS-R could help to make informed decisions on the use of immunosuppressants and the implementation of preventive measures.

Acknowledgements Funding by GSK and Spanish Foundation of Rheumatology.

REFERENCE

1. Tejera-Segura B, Rúa-Figueroa I, Pego-Reigosa JM, *et al*. Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort *BMJ Open* 2019,14;**9**(6):e028697.

O18 DATA-DRIVEN CLUSTERING OF CEREBROSPINAL FLUID PROTEOME REFLECTS CLINICAL PHENOTYPES OF SYSTEMIC LUPUS ERYTHEMATOSUS

[1]Elsa Grenmyr, [1,2]Kristoffer Zervides, [1]Seyed Morteza Najibi, [1]Birgitta Gullstrand, [3]Charlotte Welinder, [2]Jessika Nystedt, [2]Petra C Nilsson, [4,5]Pia C Sundgren, [6,7]Robin Kahn, [1]Andreas Jönsen, [1]Anders A Bengtsson. *[1]Dept. of Clinical Sciences, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden; [2]Dept. of Clinical Sciences Lund, Neurology, Lund University, Skåne University Hospital, Lund, Sweden; [3]Swedish National Infrastructure for Biological Mass Spectrometry, BioMS, Lund, Sweden; [4]Dept. of Clinical Sciences, Diagnostic Radiology, Lund University, Skåne University Hospital, Lund, Sweden; [5]Lund University BioImaging Center, Lund University, Lund, Sweden; [6]Dept. of Clinical Sciences, Pediatrics, Lund University, Skåne University Hospital, Lund, Sweden; [7]Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden*

10.1136/lupus-2024-el.28

Objective Neuropsychiatric (NP) symptoms are frequent in patients with systemic lupus erythematosus (SLE) and signs of neuronal damage can be present in patients without evident NP involvement. The cerebrospinal fluid (CSF) protein patterns may reveal insights to the pathogenesis of NPSLE. We applied a data-driven approach to investigate the clinical differences in patients with SLE, clustered by their CSF proteomic profile. In addition, we explored the association between groups of proteins and clinical and serological data.

Methods CSF samples from a cross sectional cohort of 29 female outpatients recruited irrespectively of disease activity and organ involvement, were analyzed using label-free quantification liquid chromatography tandem mass spectrometry. Hierarchical clustering of proteomic data was used to identify sample clusters and clusters were analyzed for variance of clinical traits using Kruskal-Wallis and Wilcoxon tests. Proteins were clustered in modules using Weighted Gene Co-expression Correlation Network Analysis (WGCNA). Protein modules were analyzed for correlation to clinical traits using Pearson correlation coefficient.

Results Patient cluster 1 showed highest frequency of nephritis, depression and cognitive impairment. Cluster 2 was characterized by alopecia, SSA-antibodies, and low frequency of cognitive impairment. Cluster 3 had a clinical profile of autonomic neuropathy, lupus headache and increased neurofilament light concentrations in CSF. The protein modules (M1-M6) were characterized by nervous tissue proteins (M1), lipid lifecycle proteins (M2), macrophage derived proteins (M3), plasma proteins (M4), immunoglobulins (M5), intracellular metabolic proteins (M6). Modules 1 and 2 were associated with nephritis, depression, longer disease duration and cognitive impairment, and this pattern was most pronounced in patient cluster 1. The opposite clinical profile was associated with M4 and M5, which showed inverse correlation to cognitive impairment and brain atrophy and was most distinct in patient cluster 2.

Conclusion Data-driven clustering of patients using their CSF proteome forms subgroups reflecting clinical phenotypes of SLE. Two clinical phenotypes appear, where age of disease onset, level of disease severity, renal involvement and degree of neuronal damage differentiates the phenotypes. Variances in CSF proteomic patterns may represent differences in the SLE disease process.

Acknowledgements Medical Faculty of Lund University, Skåne University Hospital Research Funding, Anna-Greta Crafoord Foundation, Greta and Johan Kock Foundation, King Gustav V 80th Birthday Foundation, Magnus Bergwall foundation, Alfred Österlund Foundation, Swedish Research Council, and Swedish Rheumatism Association

O19 CHATSLE – CONSULTING CHATGPT FOR 100 FREQUENTLY ASKED LUPUS QUESTIONS

[1]Isabell Haase, [1]Tingting Xiong, [2]Julia Greenfield, [2]Johannes Knitza*, [1]Martin Krusche*. **These authors contributed equally to this work and share last authorship; [1]University Hospital Hamburg-Eppendorf, Hamburg, Germany; [2]Institute for Digital Medicine, University Hospital Marburg, Marburg, Germany*

10.1136/lupus-2024-el.29

Objective Lupus is a rare and complex disease that affects almost all aspects of life. Inevitably, patients are constantly confronted with questions about their disease. Nevertheless,